Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

47 results about "Tissue fluorescence" patented technology

The basic premise of tissue fluorescence visualization is that it may enable clinicians to see the effects of cellular, structural, and/or metabolic activity changes in oral mucosal tissues by observing the fluorescence response of oral tissues in response to light excitation. Natural tissue fluorescence is caused by “fluorophores”.

Determination of a measure of a glycation end-product or disease state using tissue fluorescence

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise single wavelength excitation light, scanning of excitation light (illuminating the tissue at a plurality of wavelengths), detection at a single wavelength, scanning of detection wavelengths (detecting emitted light at a plurality of wavelengths), and combinations thereof. The invention also can comprise correction techniques that reduce determination errors due to detection of light other than that from fluorescence of a chemical in the tissue. For example, the reflectance of the tissue can lead to errors if appropriate correction is not employed. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.
Owner:VERALIGHT INC

Method and Apparatus to Compensate for Melanin and Hemoglobin Variation in Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual is disclosed. A portion of the skin of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can illuminate the skin and detect responsive light over a time that spans a plurality of cardiac cycles of the individual, which can, as an example, help mitigate the effects of time-varying signals such as those due to hemoglobin. The invention can also determine the amount of light to be directed to the skin, for example by controlling the time that a light source is energized. The amount of illumination light can be determined from a skin reflectance characteristic such as pigmentation or melanin in the skin. Controlling the amount of light directed to the tissue can reduce the dynamic range required of a corresponding optical system, for example by allowing a single system to accurately measure individuals with very light skin and individuals with very dark skin.
Owner:VERALIGHT INC

Determination of a Measure of a Glycation End-Product or Disease State Using Tissue Fluorescence Lifetime

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. For example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.
Owner:VERALIGHT INC

Determination of a measure of a glycation end-product or disease state using tissue fluorescence lifetime

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. For example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.
Owner:VERALIGHT INC

Method and apparatus to compensate for melanin and hemoglobin variation in determination of a measure of a glycation end-product or disease state using tissue fluorescence

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual is disclosed. A portion of the skin of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can illuminate the skin and detect responsive light over a time that spans a plurality of cardiac cycles of the individual, which can, as an example, help mitigate the effects of time-varying signals such as those due to hemoglobin. The invention can also determine the amount of light to be directed to the skin, for example by controlling the time that a light source is energized. The amount of illumination light can be determined from a skin reflectance characteristic such as pigmentation or melanin in the skin. Controlling the amount of light directed to the tissue can reduce the dynamic range required of a corresponding optical system, for example by allowing a single system to accurately measure individuals with very light skin and individuals with very dark skin.
Owner:VERALIGHT INC

Determination of a measure of a glycation end-product or disease state using tissue fluorescence preferentially from the dermis

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise single wavelength excitation light, scanning of excitation light (illuminating the tissue at a plurality of wavelengths), detection at a single wavelength, scanning of detection wavelengths (detecting emitted light at a plurality of wavelengths), and combinations thereof. The invention also can comprise correction techniques that reduce determination errors due to detection of light other than that from fluorescence of a chemical in the tissue. For example, the reflectance of the tissue can lead to errors if appropriate correction is not employed. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.
Owner:VERALIGHT INC

Reference genes for fluorescence quantitative detection of seven tissues of cherax quadricarinatus, screening method and application thereof

The invention discloses reference genes for fluorescence quantitative detection of seven tissues of cherax quadricarinatus, screening method and application thereof, and belongs to the technical fieldof molecular biology. The invention comprises reference genes GAPDH and GST, which are used for fluorescence quantitative detection of seven tissues of cherax quadricarinatus; special primers for amplifying the reference genes, nucleotide sequence (shown as SEQ ID NO.1) of a forward primer F1 and nucleotide sequence (shown as SEQ ID NO.2) of a reverse primer R1 for amplifying the GAPDH gene, nucleotide sequence (shown as SEQ ID NO.3) of a forward primer F2 and nucleotide sequence (shown as SEQ ID NO.4) of a reverse primer R2 for amplifying the GST gene. According to the invention, appropriateand stable reference genes are screened out for research on gene expression of different tissues of the cherax quadricarinatus, which is conducive to accurately analyze the gene expression rule of the cherax quadricarinatus in experiments with different purposes, and provides a necessary molecular basis for subsequent research on the molecular mechanism of the cherax quadricarinatus.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES

Moringa oil mediated activation of the alyternative cellular energy pathway in the therapy of diseases

A convenient method for activating the alternative cellular energy (ACE) pathway is described that uses ultraviolet (UV) light illumination of oil extracted from the leaves of the moringa oleifera tree. The moringa leaf oil acts as an “enerceutical,” a term defined by the inventor. The green colored moringa leaf oil can be either applied directly to areas of the skin or placed onto an impermeable barrier that is laid onto the skin. The oil displays a red fluorescence when illuminated by either mercury vapor UV emitting lamps, or bright sunlight. Smearing of the moringa leaf oil over wide surface areas of the skin in conjunction with UV illumination can be used for systemic activation of the ACE pathway. Evidence for successful systemic activation of the ACE pathway includes the appearance of direct UV light inducible tissue and body fluid fluorescence at sites other than where the oil has been applied. The induced tissue fluorescence is more yellowish-orange color, as opposed to the markedly red fluorescence of the UV light illuminated moringa leaf derived oil. As shown in other studies, systemic activation of the ACE pathway is expected to lead to clinical improvements in a wide range of infectious, metabolic and degenerative illnesses. More limited application of the UV light fluorescing moringa leaf oil to individual skin lesions can alternatively be used to specifically expedite the healing of localized skin lesions. Examples include viral infections, in which ACE pigments are known to normally accumulate.
Owner:MARTIN WILLIAM JOHN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products